| |
Cell therapy trials are complex and successfully operationalizing these studies requires careful consideration of the interplay between the patient journey and vein-to-vein logistics workflow. Download our guide to learn how to optimize this process, including key steps in study execution and improving study retention.
Premier Research. Built for Biotech℠
|
|
Today's Big NewsJun 22, 2023 |
| By Max Bayer Federation Bio is joining the layoff ranks, cutting loose an undisclosed number of employees. The company dosed the first patient in its first clinical trial at the end of 2022. |
|
|
|
By Max Bayer Nutcracker Therapeutics has laid off a dozen employees, according to two sources familiar with the decision. A spokesperson declined to comment on the layoffs. |
By Nick Paul Taylor Talaris Therapeutics’ plans have crystallized. Having stopped its transplant programs and hunkered down, the biotech has entered into a reverse merger that will provide Tourmaline Bio with a platform for taking an ex-Pfizer drug candidate into midphase clinical trials. |
Sponsored by Invest Puerto Rico Puerto Rico is becoming the best place in the world to conduct R&D activities for emerging technologies. Could your organization maximize growth potential by capitalizing on Puerto Rico’s unique tax incentives & culture of innovation? |
By Max Bayer Aeglea is staying on Wall Street, for now, buying up Spyre Therapeutics and tacking on $210 million through a private placement. The company was on the hunt for strategic alternatives after laying off almost all its remaining staff in April. |
By James Waldron Bayer-partnered Azitra will use the proceeds of a $7.5 million IPO to push its engineered bacterial treatments into the clinic. |
By Gabrielle Masson UniQure’s stock has hit a six-year low after an interim data drop for a study evaluating its investigational gene therapy for Huntington’s disease. |
By Nick Paul Taylor Zenyaku Kogyo is lining up a challenge to Sanofi and Regeneron’s blockbuster Dupixent in Japan, paying Aslan Pharmaceuticals $12 million upfront for local rights to a midphase eczema drug candidate. |
By Helen Floersh Startup Amplifica is looking to turn the molecule that makes hair grow in moles into a viable therapy for androgenetic alopecia. |
By Joseph Keenan Leal Health, an AI-powered health tech firm, expanded its platform with the addition of FDA-approved cancer treatment decision support—a first-of-its-kind tool in the industry. |
By Zoey Becker Aldeyra's bid for an approval in primary vitreoretinal lymphoma wasn't supported by clinical trial data as the company doesn't think a study in the rare and fatal disease is feasible, CEO Todd Brady, M.D., Ph.D., said in a statement. Now, the company hopes its drug can be used through an expanded access program. |
By Kevin Dunleavy The CDC's Advisory Committee on Immunization Practices has recommended that adults 60 and older—in consultation with their doctors—receive vaccines to prevent lower respiratory tract disease caused by respiratory syncytial virus. The thumbs-up, however, was anything but enthusiastic. |
By Paige Minemyer Even in the face of substantial headwinds, dealmaking in the healthcare industry hasn't fallen off, according to a new analysis from PwC. |
By Zoey Becker Trade group PhRMA is the latest to go after the IRA in a lawsuit claiming violations of the Fifth and Eighth amendments. The suit follows similar legal efforts by Merck and Bristol Myers Squibb. |
Fierce podcastsDon't miss an episode |
| | This week on "Podnosis," we talk about the momentum behind addressing health equity challenges. Also under discussion is how social drivers of health are finally being recognized by CMS. |
|
|---|
|
|
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperAutoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
| WhitepaperDiscover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| eBookSee how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
| WhitepaperThis paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
